or
Remember me
Back
Bioxytran, Inc. ($BIXT) stands at the forefront of biotechnology, leveraging artificial intelligence to revolutionise drug design. With a market cap of $19.04 million and 165.58 million outstanding shares, the company's focus on glycovirology and hypoxia positions it as a leader. In the OTC market, the dynamic 52-week range of 0.071–0.55 reflects Bioxytran's commitment to transformative advancements. Authorised shares of 300 million and a float of 28,687,245 underscore the strategic groundwork for innovative progress in virology, degenerative disease, and hypoxia.
Receive investor kits and email updates from Stockhouse and directly from these companies.
